FOCUS
T he blood-brain barrier (BBB) protects the brain from fluctuations in plasma concentrations and toxins capable of disturbing neural function. The BBB also restricts the delivery of drugs to the brain, as it is impermeable to most biological and small-molecule therapeutics.
1 Limitations in drug transport across the BBB has made treating CNS tumors difficult. 37, 48, 49, 52 Magnetic resonance-guided focused ultrasound (MRgFUS) uses acoustic waves in the ultrasound spectrum to transiently raise the temperature or activate molecules at a specific location. This emerging technology is used primarily for thermal ablation of central brain locations, such as for the treatment of essential tremor and Parkinson's disease. 5, 21, 41, 50 MRg-FUS is an image-guided, noninvasive treatment option that can be used to manipulate the BBB and achieve focal CNS tumor drug delivery of systemically administered treatments.
Background The Blood-Brain and Blood-Tumor Barriers
The BBB is composed of endothelial cells, astrocyte foot processes, and pericytes. 4 Tight junctions between these cells form a barrier, preventing transcellular and paracellular diffusion of most substances from entering the brain. Multiple transport systems, enzymes, and receptors involved in the regulation of the BBB have been identified. 42 Tight regulation of the BBB maintains cerebral function by preventing the passive crossing of cells and molecules that are capable of inducing inflammation and damage to the CNS. 13 Consequently, methods of bypassing the BBB for therapeutic effect should be targeted and transient to prevent global brain injury.
The blood-tumor barrier (BTB), located between the malignancy and blood vessels, is formed after the tumor is larger than 0.2 mm 3 . 32 As the tumors grow, astrocyte foot processes are displaced from blood vessels by malignant cells, leading to perpetual fenestration of the BBB. 58 Although the level of disruption often remains subtherapeutic, BTB-targeted drug delivery holds promise for effective treatment of brain tumors through increased permeability. therapeutic threshold concentration but must remain at a low concentration peripherally and within normal brain to limit side effects. Although exceptions exist, drugs that cross the BBB are typically lipid soluble, uncharged, less than 500 D, and not rapidly transported out of the CNS. 45 For example, erlotinib (Tarceva) is an efficacious drug in the treatment of non-small cell lung cancer brain metastases, with all of the aforementioned properties. 22 Designing effective drugs with all of these characteristics has been challenging, and recent efforts have focused on increasing CNS bioavailability through other means.
Prior attempts to enhance drug delivery have affected the brain globally and carry the potential for significant toxicity.
13 Drug delivery systems, such as nanoparticles modified with brain-or tumor-targeting receptors have been used to penetrate the BBB. 23 Radiation therapy, commonly used for the treatment of brain tumors, disrupts the BBB by causing endothelial apoptosis. 27 Intranasal injections are capable of bypassing the BBB but can only be used with subtherapeutic volumes for most drugs due to the risk of olfactory damage. 33 Direct surgical injection of drugs into the brain parenchyma and spinal fluid requires large doses and carries risks of infection, toxicity, iatrogenic damage, and drug spread outside of the intended target. 35, 36 Bis-chloroetheylnitrosourea (BCNU) wafers placed in the brain tumor resection cavity increase local drug delivery; however, this treatment method has associated complications and generates MRI artifact. 6 Convection-enhanced delivery slowly infuses drugs using surgically placed small-diameter catheters to saturate the target site and limit regional spread. 14 The limitations of these drug-to-brain delivery approaches have led to the search for safe, less invasive, and more effective alternatives. MRgFUS holds great promise for focused, repeatable disruption of the BBB to enhance systemic treatment efficacy.
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MRgFUS and Microbubbles Focally Disrupt the BBB
MRgFUS with microbubbles has been shown to transiently disrupt the BBB for up to 24 hours. 26, 38, 43 Focused ultrasound (FUS) can cause expansion of the gaseous microbubbles until they rupture in a process termed inertial cavitation. 43 Lower FUS power levels instead lead to oscillation of the microbubbles, known as stable cavitation. Stable cavitation temporarily increases the permeability of the BBB, either through mechanical disruption or by inducing physiological changes in BBB cells (Fig.  1 ). There is evidence for both of these mechanisms; transcellular and paracellar passage of molecules has been found with FUS.
7 MRgFUS focal disruption of the BBB can increase the therapeutic concentration within a brain tumor of systemically administered drug while limiting toxicity to the normal brain and systemic organs. 53 For example, MRgFUS delivered intravenous methotrexate to the brains of healthy rabbits at concentrations 13 times higher than intravenous methotrexate delivery alone (p < 0.01) and more than 3 times higher than methotrexate delivery via the internal carotid artery without MRgFUS (p < 0.01). 40 Thus, MRgFUS can reduce side effects of chemotherapeutic agents by requiring a lower systemic dose to reach a desired brain tumor tissue concentration. MRI guidance allows for not only identification of the lesion to be targeted but also dynamic feedback on the extent of BBB disruption via contrast leakage. 
MRgFUS and Brain Tumors MRgFUS and Microbubbles Allow Systemic Chemotherapeutics to Cross the BTB
Several studies have suggested that the ability of MRg-FUS and microbubbles to disrupt the BBB for passage of chemotherapeutics also extends to the BTB. 29, 47, 59 In a rat brain glioma model of intravenous doxorubicin (DOX), Park et al. reported that MRgFUS increased DOX concentrations in gliomas by more than 2.5 times at 1 hour posttreatment compared with gliomas not receiving MRg-FUS (p < 0.01). 47 At 24 hours posttreatment, DOX concentrations in gliomas with MRgFUS were almost 14 times higher than those without MRgFUS (p < 0.001). The authors also found that gliomas with MRgFUS had no sig- nificant change in DOX concentration between 1 hour and 24 hours posttreatment. In contrast, DOX concentrations at 24 hours posttreatment in gliomas without MRgFUS were approximately 20% of the 1-hour posttreatment levels (p < 0.01). This suggests that MRgFUS may not only increase the delivery of drugs across the BTB but also prolong the time on target. The only side effects reported were regions of petechiae smaller than 1 mm that represented extravasation of red blood cells due to blood vessel damage. The BBB and BTB may respond differently to the same dose equivalent of MRgFUS depending on the systemic treatment or tumor. In the study by Park et al., 47 DOX was able to cross the BTB at higher rates than the healthy BBB, but in another study using a similar model with BCNU, the BTB was more challenging to disrupt with MRgFUS than the BBB. 29 MRgFUS at the same dose equivalent increased delivery of BCNU into normal brain tissue by 340% in normal rats, but by only 202% in the tumor-implanted rats (p < 0.05). This suggests that MRg-FUS disruption of the BTB may be treatment dependent, and not directly corollary to disruption of the BBB. Figure  2 shows results from an unpublished experiment in tumorimplanted mice using MRgFUS and microbubbles, which is representative of MRgFUS in animal models.
Combining Systemic Chemotherapy With MRgFUS Disruption of the BTB Improves Outcomes
As MRgFUS disrupts the BTB and increases systemic drug penetrance, tumors are more effectively treated and survival is improved. For example, in a rat glioma model with systemic delivery of BCNU, the addition of MRg-FUS to disrupt the BTB improved the median survival time compared with no treatment (53 days vs 29 days, p < 0.0015) or BCNU alone (53 days vs 32 days, significance not reported). 29 The improvement in outcomes required concomitant delivery of systemic chemotherapy, as MRg-FUS alone showed no benefit. Similar results were found with the use of temozolomide (TMZ) with MRgFUS in rat glioma, with a significantly increased median survival time over no treatment (23 days vs 20 days, p < 0.001). TMZ alone did not show a significant difference compared with no treatment (21 days vs 20 days, p = 0.09). 59 MRgFUS+TMZ slowed tumor growth significantly more than TMZ alone (p = 0.002), with the 1-week tumor growth being 21 times the starting volume without MRgFUS and 5 times with MRgFUS. MRgFUS improves the delivery of systemic chemotherapy and increases treatment efficacy, although the dose-response relationship has not been explored in depth.
Liposome Encapsulation and MRgFUS-Enhanced Drug Delivery
Liposome encapsulation of systemic chemotherapies effectively reduces systemic toxicity. 34 This is due in part to lower levels of chemotherapy at nontumor sites, although the exact mechanism is unclear. Recent studies have combined liposome-encapsulated DOX (LeDOX) with MRgFUS-enhanced drug delivery. An early study in healthy rats showed that LeDOX paired with MRgFUS could achieve target therapeutic levels of DOX in the brain, with nontargeted brain regions having significantly lower DOX concentrations. 55 A study in a rat glioma model with a single LeDOX+MRgFUS treatment showed a significantly increased median survival time compared with no treatment (31 days vs 25 days, p < 0.001), whereas LeDOX alone could not produce significant results (29 days vs 25 days, p = 0.17). 56 Another rat glioma model 3 Side effects were noted in the LeDOX+MRgFUS rats, including impaired activity (2 of 8), brain tissue damage and/or necrosis (4 of 8), and intratumoral hemorrhage (1 of 8) after 3 treatments of 5.67 mg/kg LeDOX+MRgFUS. The only side effect noted in LeDOX-alone group was impaired activity (1 of 6). Neither study reported the significance of LeDOX+MRgFUS versus LeDOX alone. Recent evaluation of a stabilized long-circulating liposomal paclitaxel (LePTX) in a mouse model of glioblastoma showed results similar to the Le-DOX studies, with a significantly improved median survival time (47 days vs 39 days, p < 0.001) compared with no treatment. 51 Again, results were not directly compared with LePTX alone, but LePTX alone failed to demonstrate significance compared with no treatment (41 days vs 39 days, p = 0.07).
Modified liposomes have also been shown to improve MRgFUS-facilitated delivery of systemic chemotherapeutics. For example, in a mouse glioma model, LeDOX conjugated with a peptide ligand for interleukin (IL)-4 receptor, highly expressed in human brain tumors, showed a significant improvement in median survival time compared with no treatment (15 days vs 9 days, p = 0.0001) or ligand-conjugated LeDOX alone (15 days vs 3 days, p = 0.017). 60 DOX encapsulated in cationic liposomes (cLe-DOX) accumulate preferentially in tumor tissue due to their positive charge. MRgFUS+cLeDOX modestly improved median survival over cLeDOX alone in a rat glioma model (81 days vs 35 days, p < 0.001), both of which were significantly greater than no treatment (17 ± 2 days, p < 0.001). 28 Neither study compared the modified liposomes to unmodified liposomes, so it is unclear if these present an advantage.
Nanoparticle Conjugation and MRgFUS
Nanoparticles present an alternative to liposomal encapsulation, which has been shown to have its own potential side effects. 24 Magnetic nanoparticle (MNP) drug delivery promises to be highly synergistic with MRgFUS. MNPs can be conjugated to chemotherapy and enriched in a targeted area by using a magnetic field generated by an external magnet to attract them, which is termed magnetic targeting (MT).
11 MNPs also act as a contrast agent, potentially eliminating the need for gadolinium in MRg-FUS treatment delivery. 57 MNPs have difficulty crossing the BBB, but combined with MRgFUS, they can accumulate at high levels in brain tissue. 30 The system operates in an open-then-pull manner, in which the BBB is first permeabilized by MRgFUS and then circulating MNPs are pulled through the permeabilized area of disrupted BBB via a magnetic field.
Preliminary studies in animals have shown promise for the combination of MNPs and MRgFUS to improve treatment delivery to brain tumors. For example, a rat model of glioma treated with epirubicin-conjugated MNP + MRgFUS+MT showed a 2.4-fold increase in MNP accumulation compared with the contralateral hemisphere, whereas MNP+MRgFUS without MT achieved a 1.2-fold increase (significance not reported). 30 This increase in MNP accumulation led to a 16-fold increase in the concentration of epirubicin in MRgFUS+MT-treated brain tissue, compared with MRgFUS alone (significance not reported). The MNP+MRgFUS+MT-treated group showed prolonged survival time compared with no treatment (31 days vs 18 days, p = 0.0002) or MNP+MRgFUS without MT (30.5 days vs 20 days, significance not reported). Tumor growth over 7 days was also delayed in the MNP+MRgFUS+MT group compared with no treatment (106% ± 24% vs 313% ± 103%, significance not reported). The authors noted, however, that performing MT within the longer distances of human anatomy would likely require a superconducting magnetic coil or MNPs that are more strongly magnetic. Similar conclusions were found when using BCNU. 10 , significance not reported). Results from low-and high-dose MNPs demonstrated that this effect was dose dependent.
Efforts at further simplifying MNP-containing protocols have resulted in microbubbles that are conjugated with superparamagnetic iron oxide nanoparticles (SPIONs, a type of MNP) and loaded with DOX. 19 Thus, a single substance combines the functionality of microbubbles, gadolinium contrast, and chemotherapy-conjugated MNPs with delivery enhanced by MRgFUS+MT. In a rat glioma model, SPION deposition in MT+MRgFUS increased by 4-fold (p < 0.01) compared with the contralateral, nontargeted hemisphere. MRgFUS alone and MT only enhanced accumulation by 2.7-fold (p < 0.01) and 2.3-fold (p < 0.05), respectively. Similarly, the MT+MRgFUS group increased DOX deposition in the treated hemisphere by 2-fold (p < 0.05) compared with the control hemisphere. The followup study used a different formulation that improved DOXcarrying capacity and R2 relaxivity, thus allowing the authors to track tissue accumulation more accurately via MR relaxometry.
17 SPION-DOX complexes accumulated in MRgFUS-targeted brain tissue at a 2.8-fold (p < 0.05) higher concentration when MT was applied versus without it. Likewise, DOX deposition into targeted brain tissue was enhanced by more than 2.1-fold (p < 0.05) with MT. The authors found that the MR R2 value and SPION concentration were highly correlated (R 2 = 0.83), and furthermore, SPION concentration was highly correlated (R 2 = 0.79) with DOX accumulation. The combination SPION-DOX microbubbles may prove useful due to the ease with which dosing could be monitored through imaging.
Chemotherapy With Modified Microbubbles and
Ultrasound-Guided FUS
Microbubble-encapsulated BCNU used with ultrasound-guided FUS (USgFUS) prolonged the half-life and reduced peripheral uptake of BCNU, decreasing tumor progression in glioma rats. 54 In particular, liver deposition of BCNU 10 minutes after treatment with microbubble-encapsulated BCNU was 9-fold than that of BCNU only (significance not reported), whereas encapsulated BCNU with FUS was 5-fold less than that of BCNU (p < 0.01, with FUS). Another study showed that USgFUS could oscillate BCNU-loaded microbubbles at their resonant frequency, producing stable cavitation and reducing the chance of red blood cell extravasation. 18 The median survival was improved compared with no treatment (28 days vs 18 days, p = 0.001), but no comparison was made with free BCNU with unmodified microbubbles. Micro-bubbles can be further modified with moieties designed to target tumor markers like VEGF, which one study reported could be used with USgFUS to prolong survival in rat glioma. 20 The experimental group had increased median survival compared with no treatment (42 days vs 19 days, p = 0.007) or BCNU alone (42 days vs 23 days, significance not reported). Notably, the nontargeted BCNUloaded microbubbles with FUS did not have a significant increase in median survival compared with no treatment. Liver accumulation was 3-fold less in the VEGF-targeted experimental group than in the nontargeted group (p < 0.05). Whether chemotherapy is loaded onto liposomes, MNPs, or microbubbles, tumor-targeting moieties will be a part of future MRgFUS-coupled drug delivery systems.
Immunotherapy and MRgFUS
Research on immunotherapy usage with MRgFUS for brain tumors has largely been limited to delivery of HER2-targeting antibodies for treatment of breast cancer metastases. In a mouse model, FUS treatment effectively delivered trastuzumab, with dose limited by red blood cell extravasation. 25 Without MRgFUS, brain tissue levels of trastuzumab were undetectable in all but one case. In a rat model of HER2-positive human breast cancer metastases to the brain, Park et al. reported that MRgFUSdelivered trastuzumab increased the median survival time compared with no treatment (83 days vs 63 days, p = 0.008) and trastuzumab only (83 days vs 71 days, not significant), with a significant reduction in tumor volume (p < 0.05 at week 7) compared with all other groups. 46 Of note, this effect was derived from a subset of the experimental group, as 6 of 10 experimental mice were nonresponders. Rats treated with MRgFUS and peripherally administered HER2-specific NK-92 cells showed a longer mean survival time (times unreported, p < 0.05).
2 Similar to the study by Park et al., 46 about half of the treatment animals were nonresponders, following a survival curve similar to animals without treatment. The study found no histological signs of red blood cell extravasation, although the authors noted that a week or more elapsed between the last MRgFUS treatment and euthanization. In a rat glioma model, FUS increased the intraperitoneal IL-12 concentration in the brain by almost 2.9-fold (p = 0.003) versus without FUS. 9 The IL-12 + FUS significantly increased T-lymphocyte presence inside the tumors com- 2-fold, p < 0.05; cytotoxic-to-regulatory T-cell ratio increase: 2.5-fold, p < 0.001). This effect was not seen in healthy rats or systemically in tumor-implanted rats. Median survival time was increased compared with no treatment (30 days vs 21 days, p < 0.001) and IL-12 alone (30 days vs 26 days, significance not reported). Immunotherapies could be rapidly integrated into MRgFUS protocols, should targeting in animal models continue to show promise.
Gene Therapy and USgFUS
FUS as a means to deliver DNA-loaded microbubbles is an emerging field. Folate-conjugated cationic microbubbles (cMBs) containing DNA combined with ultrasound targeting successfully transfected tumor cells in a rat glioma model. 16 Treatment with FUS and folate-conjugated cMBs improved reporter gene expression in tumor tissue by 4.7-fold compared with direct injection (p < 0.01) and 1.5-fold (significance not reported) compared with cMBs without folate conjugation. Expression was only found within the tumor. An additional study in a rat glioma model used DNA-loaded cMBs conjugated with VEGFR2-targeted monoclonal antibodies. 8 Reporter gene expression in tissue receiving targeted or nontargeted cMBs + FUS was 3.7-fold (p < 0.01) and 2.3-fold (p < 0.05) higher, respectively, than direct DNA injection into the tumor. The authors then tested the cMBs with a suicide gene previously tested with ultrasound, pHSV-TK, which converts ganciclovir into a product that terminates DNA replication and results in tumor death. 61 The cMBs+FUS decreased tumor volume at day 25 compared with direct injection (9. , significance not reported). Both targeted and nontargeted cMBs had significantly decreased tumor volume (p < 0.01) and increased median survival time (p < 0.05) compared with untreated controls. Among brain tumor therapeutics used with FUS, gene therapy is the least developed. Incorporation of MR guidance as this technology nears clinical trials will be necessary for imaging through the human skull.
Limitations
Promising preclinical studies in animal models will need to be tested thoroughly in humans. A Phase 1 clinical trial should be conducted to evaluate toxicity and determine the safe levels for MRgFUS strength, and the choice, dosing, and timing of systemic chemotherapeutic agents. Compared with rodents, the thicker human skull and the longer distances to any given point within the human cranium will attenuate ultrasound, requiring higher power. Likewise, tumor depth may limit which types of lesions could be reasonably treated. 39 Severe or symptomatic peritumoral edema may be exacerbated by further disruption of the BTB. Setups with stereotactic frames would be difficult to use in patients requiring multiple FUS treatments, but frameless designs, such as the NaviFUS system, are being developed. 31 A risk of hemorrhage has been documented in animal models, but it is uncertain how this will translate to humans. 25, 47 The only relevant study in humans is a nonrandomized, single-arm Phase 1 clinical trial (registration no. NCT02986932, clinicaltrials.gov) evaluating the safety of BBB opening with FUS in 6 patients with Alzheimer's disease. Patients will be followed out to 2 months after opening a 3 × 3-cm area of BBB. Results have not yet been released. Experiences with high-intensity focused ultrasound in the ablation of brain tumors in human patients have yielded minimal side effects other than pain symptoms possibly related to dural heating.
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Conclusions
MRgFUS holds significant promise for less invasive, repeatable, targeted drug delivery to brain tumors. It may act synergistically with drug delivery technologies that can further enhance delivery and treatment release within the desired tissue, including nanoparticles and liposomes. In animal models, MRgFUS has been shown to successfully enhance the delivery of chemotherapy, immunotherapy, and gene therapy with corresponding improvements in treatment efficiency, tumor progression, and overall survival.
